RecruitingBladder Cancer
Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
BCDx is a urine-based multi-omic assay for early cancer recurrence detection in patients with a history of bladder cancer. This prospective, blinded study evaluates its efficacy in detecting recurrent NMIBC, offering a noninvasive monitoring solution.
Sponsor: Early is Good Inc.
You may qualify if…
- ✓ Patients 18 Years and older
- ✓ Patients who have been diagnosed with incident or recurrent NMIBC within the past 2 years and undergoing standard of care/routine monitoring cystoscopy.
- ✓ Patients who are able to provide legally effective informed consent.
- ✓ Patients who are able to provide minimum 30mL of voided urine.
You may not qualify if…
- ✕ Patients planning to undergo radical cystectomy or chemotherapy-radiation for Urothelial Cell Carcinoma.
Where it's recruiting
Source: ClinicalTrials.gov · NCT05982561 · last updated 2026-04-23